SCHEMBL19639909

SCHEMBL19639909

O=S(=O)(O)c1ccc2[nH]nc(Br)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
HPGD P15428 2/20 0.41
THRB P10828 2/20 0.41
BLM P54132 2/20 0.41
F2 P00734 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
MAPT P10636 1/20 0.41
PTGS1 P23219 1/20 0.41
KDR P35968 1/20 0.41
WRN Q14191 1/20 0.41
PTPN11 Q06124 4/20 0.40
HDAC6 Q9UBN7 1/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP6 P55212 1/20 0.39
JAK2 O60674 4/20 0.39
PDPK1 O15530 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639911 0.87 PARP1 (0.42) ALDH1A1TDP1HPGDTHRBBLM
SCHEMBL11614800 0.81 JAK2 (0.56) ALDH1A1KDRHSD17B10CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL27679753 0.79 JAK2 (0.40) ALDH1A1TDP1HPGDTHRBBLM
Hydrochloric Acid SCHEMBL27659735 0.78 JAK2 (0.38) ALDH1A1TDP1HPGDTHRBBLM
SCHEMBL29534191 0.72 PTPN11 (0.54) ALDH1A1TDP1HPGDTHRBBLM
SCHEMBL3267890 0.72 PTPN11 (0.54) ALDH1A1TDP1HPGDTHRBBLM
SCHEMBL254651 0.70 MAPT (0.61) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL16125483 0.70 KIF11 (0.45) ALDH1A1HPGDMAPTJAK2PDPK1
SCHEMBL2467763 0.69 JAK2 (0.53) ALDH1A1TDP1HPGDMAPTJAK2
SCHEMBL15332567 0.69 FADS1 (0.49) HPGDJAK2PDPK1CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-08-25 US disclosed
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-07-04 US disclosed
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) RORA, RORB, RORC ALDH1A1 590/4885TDP1 4743/4885HPGD 998/4885
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC ALDH1A1 587/4885TDP1 4759/4885HPGD 983/4885
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC ALDH1A1 587/4885TDP1 4759/4885HPGD 983/4885
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) RORA, RORB, RORC ALDH1A1 587/4885TDP1 4759/4885HPGD 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.